Pharmaceutical Executive
Pharmaceutical Executive-02-01-2005
Pharmaceutical Executive-01-01-2005
Pharmaceutical Executive-01-01-2005
Pharmaceutical Executive-12-01-2004
Pharmaceutical Executive-12-01-2004
Pharmaceutical Executive-11-01-2004
Pharmaceutical Executive-11-01-2004
Pharmaceutical Executive-10-01-2004
Pharmaceutical Executive-10-01-2004
Volume: 0
Issue: 0
Pharmaceutical Executive-09-01-2004
Pharmaceutical Executive-09-01-2004
Pharmaceutical Executive-08-01-2004
Pharmaceutical Executive-07-01-2004
Pharmaceutical Executive-07-01-2004
Pharmaceutical Executive-06-01-2004
Pharmaceutical Executive-05-01-2004
Pharmaceutical Executive-05-01-2004
Pharmaceutical Executive-04-01-2004
Pharmaceutical Executive-03-01-2004
Pharmaceutical Executive-03-01-2004
Volume: 0
Issue: 0
Pharmaceutical Executive-02-01-2004
Pharmaceutical Executive-01-01-2004
Pharmaceutical Executive-01-01-2004
Pharmaceutical Executive-12-01-2003
Pharmaceutical Executive-11-01-2003
Pharmaceutical Executive-10-01-2003
Pharmaceutical Executive-10-01-2003
Pharmaceutical Executive-09-01-2003
Pharmaceutical Executive-08-01-2003
Pharmaceutical Executive-07-01-2003
Advertisement
Advertisement
Trending on PharmExec
1
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
2
What the Peptide Advisory Vote Actually Means: Q&A with James LaValle
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
Focusing on Asset Acquisition Over Building a Single Platform Technology
5